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To assess the response rate and the tolerance of irinotecan as first-line therapy, 40 patients with metastatic gastric cancer received
irinotecan 350mgm
 2 every 3 weeks administered as a 30min infusion. Among the 35 patients evaluable for response, two
complete and five partial responses were recorded (response rate: 20.0% (95% CI:8.4–36.9%)). In total, 16 patients achieved stable
disease and 12 progressive disease. In all, 66 percent of the patients benefited from tumour growth control. The median time to
progression was 3.0 months (95% CI: 2.3–4.4%). The median overall survival was 7.1 months (95% CI: 5.2–9.0%). The probability of
being alive at 6 months and 9 months was 61.0 and 32.4%, respectively. The median number of cycles per patient was 3 (range 1–
14), and the relative dose intensity was 0.98. The most common grade 3–4 toxicities by patients were diarrhoea 20%, asthenia 10%,
nausea 7.5%, vomiting 5.0%, abdominal pain 5%, neutropenia 38.5%, leucopenia 28.2%, anaemia 12.8% and thrombocytopenia 5.1%.
Febrile neutropenia occurred in 12.5% of patients. These findings indicate that irinotecan is active and well tolerated in patients with
metastatic gastric adenocarcinoma and warrants further evaluation in this clinical setting.
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Gastric carcinoma is a highly aggressive disease with an
exceedingly poor prognosis for patients with advanced stage
disease. It is the fifth most common malignancy in the European
Union and is the fourth most common cause of cancer death after
lung cancer for men, breast cancer for women and colorectal
cancers for both. While a decreased incidence of gastric
adenocarcinoma has been observed for several decades in Western
countries, this has been accompanied by an increase in the
incidence of tumours of the gastro-oesophageal junction and a
simultaneous shift towards poorly differentiated adenocarcinomas
(Blot et al, 1991). Most gastric tumours are diagnosed at an
advanced stage, and surgery, even if performed with curative
intent, gives disappointing results with an overall 5-year survival of
10% (Maruyama et al, 1987; Wanebo et al, 1993; Bonenkamp et al,
1999). The causes of surgical failure are a combination of local
recurrence and distant metastases.
Chemotherapy is able to prolong survival relative to best
supportive care (Murad et al, 1993; Pyrhonen et al, 1995; Glimelius
et al, 1997). Response rates of 5%–21% have been reported for
single-agent chemotherapy, with 5-fluorouracil (5-FU), in chemo-
naive patients (Wils and Bleiberg, 1989; Loehrer et al, 1994). Other
agents, when used as monotherapy, have produced response rates
as follows: paclitaxel 20% (Ajani et al, 1998), adriamycin 24%
(O’Connell, 1985), docetaxel 25% (Sulkes et al, 1994), cisplatin 25%
(O’Connell, 1985), UFT 28% (Takiuchi and Ajani, 1998) and
mitomycin C 30% (Comis and Carter, 1974).
At present, combination chemotherapy is the standard treat-
ment for advanced disease. Several regimens have been used
(FAM, FAMTX, ECF, EAP, ELF, FP), but those containing
cisplatinum in combination with infusional 5-FU are the most
widely accepted. Unfortunately, any improvements in response
rate only translate into a small benefit in terms of overall survival,
and median durations of survival that are still between 6 and 10
months (Ko ¨hne et al, 2000). Thus, any active agent with a new
mechanism of action deserves further investigation.
Irinotecan (CPT-11, Campto
s) is an S-phase-specific, semisyn-
thetic derivative of camptothecin which interferes with DNA
replication and cell division through its potent interaction with the
enzyme topoisomerase I. A statistically significant survival
advantage has been shown for irinotecan as a single agent, in
patients with colorectal cancer who had failed on prior 5-FU-based
therapy (Cunningham et al, 1998; Rougier et al, 1998), and for
irinotecan in combination with infusional and bolus 5-FU/folinic
acid regimens, first line in the treatment of patients with metastatic
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lcolorectal cancer (Douillard et al, 2000; Saltz et al, 2000). In
metastatic gastric cancer, the activity of irinotecan as a single agent
has been reported by Futatsuki et al. (1994) in 60 evaluable
patients treated at a dose of 100mgm
 2 every week or 150mgm
 2
every 2 weeks. The response rate in this trial was 23%. In two
phase II studies (Wakui and Taguchi, 1992; Lin and Hecht, 2000)
using different schedules of irinotecan: 100mgm
 2 once per week,
150mgm
 2 every 2 weeks, 200mgm
 2 every 3 weeks,
50mgm
 2day for 3 days bi-weekly (Wakui and Taguchi, 1992)
and 125mgm
 2 weekly for 4 weeks followed by 2 weeks rest (Lin
and Hecht, 2000), the response rates were 12 and 17%, respectively.
The present study investigated the response rate, survival and
toxicity profile of irinotecan, 350mgm
 2, as a single agent,
administered every 3 weeks, in chemotherapy naive patients with
metastatic gastric adenocarcinomas.
PATIENTS AND METHODS
Patient selection
Patients with a histologically confirmed diagnosis of metastatic
gastric adenocarcinoma with at least one bidimensionally measur-
able lesion were eligible for recruitment into the study. Other
eligibility criteria were: age between 18 and 70 years old, a WHO
performance status p2, no prior chemotherapy (neither palliative
nor (neo)adjuvant), at least 3 weeks from surgery and 6 weeks
from radiotherapy, adequate haematopoietic (haemoglobin4
10gdl
 1, absolute neutrophil count (ANC)42.0 10
9l
 1,
platelets4150 10
9l
 1), renal (adequate serum creatinine
p1.25 upper normal limit (UNL)) and hepatic (total serum
bilirubin p1.25 UNL, AST and ALTp3 UNL or in case of liver
metastasis, total bilirubinp1. 5 UNL, AST and ALTp5 UNL)
function. Exclusion criteria consisted of locally advanced disease
without distant metastases, tumour types other than adenocarci-
noma (leiomyosarcoma or lymphoma), the presence of a central
nervous system (CNS) metastasis, pregnancy or lactation, prior or
current history of chronic diarrhoea, bowel obstruction, subacute
bowel obstruction, Crohn’s disease or ulcerative colitis, other
serious illnessess or medical conditions (e.g. current infection;
active disseminated intravascular coagulation), past or concurrent
history of neoplasm other than gastric carcinoma, except for
curatively treated non melanoma skin cancer or in situ carcinoma
of the cervix. All patients provided written informed consent prior
to entry into the study. The study was approved by the Ethics
Committees of all the participating institutions.
Treatment
Treatment consisted of irinotecan i.v. 350mgm
 2 administered
day 1 every 3 weeks as a 30min infusion. Two subsequent dose
reductions (to 300mgm
 2 and if needed to 250mgm
 2) were
planned in the case of either haematological toxicity as defined by
a nadir with grade 4 neutropenia, grade 3–4 neutropenia with
concomitant fever X38.11C, or in the case of severe diarrhoea
(grade 3–4 NCI-CTC) requiring rehydration. Treatment was
delayed by 1–2 weeks if the ANC was o1.5 10
9l
 1 or the
platelet count was o150 10
9l
 1 on the day of treatment.
Treatment was to be given until progressive disease (PD),
unacceptable toxicity or withdrawal of patient consent. Patients
with stable disease (SD) and no symptomatic improvement at the
first assessment were allowed to switch to a salvage treatment.
Premedication with antiemetics as well as treatment with atropine
in the case of previous severe cholinergic syndrome was required.
Efficacy assessment
Response rate was the primary end point of this study. A baseline
tumour evaluation was required within the 15 days prior to
registration. Tumour assessments while on study were performed
every two cycles. WHO guidelines were used to assess tumour
response. All responses were confirmed at least 28 days later.
Radiological documentation for all patients was reviewed by a
panel of external experts. To be evaluable for response, a patient
had to have at least one bidimensionally measurable lesion, to have
received at least two cycles of treatment and have been assessed
with the same method of measurement as at baseline. Patients who
progressed before the first assessment at cycle 2 were considered to
have PD. Subjective patient improvement (yes/no) was assessed by
the investigator at each cycle. Survival was defined as the interval
from the first day of treatment to the date of death. The time to
progression (TTP) was the interval from the first day of treatment
to the date of progression.
Safety assessments
Patient history, baseline signs and symptoms, full blood count and
chemistry (alkaline phosphatase, AST, ALT, total and direct
bilirubin, electrolytes and creatinine) were performed within the
8 days prior to registration and thereafter prior to the commence-
ment of each cycle. A blood count was performed weekly. The NCI
common toxicity criteria (NCI-CTC) scale was used in grading the
adverse events during the study. Adverse events, signs and
symptoms were determined at the end of each cycle. All adverse
events occurring within 30 days of the last irinotecan infusion were
followed. Adverse events related to irinotecan that were still
ongoing 30 days from the time of the last irinotecan infusion were
also followed until resolution.
Statistical methodology
The purpose of this phase II trial was to investigate the efficacy of
irinotecan as a single agent in 30 evaluable patients with advanced
gastric carcinoma who had received no prior chemotherapy. A two
stage modified Fleming design (Fleming, 1982) was used. A total of
15 patients were planned at each stage except in case of early
termination after the first stage. If no responses were observed in
the first stage, the trial was to be stopped. If at least one response
was observed, at least 15 additional evaluable patients were to be
accrued. If less than four responses were observed in the total
population of 30 patients, the final conclusion was to be that the
activity of irinotecan was disappointing. If at least four responses
were observed, then the activity of irinotecan as demonstrated in
this study would have been sufficiently promising to warrant
further development. The procedure tests, the null hypothesis (H0)
as formulated for this study that the true response rate is p5% vs
the alternative hypothesis (HA) that the true response rate is
X25%, with a significance level of 6% and a power of 96%.
Survival curves were estimated by the Kaplan–Meier method. The
confidence interval of the median was calculated using the
Brookmeyer and Crowley method (Brookmeyer and Crowley,
1982).
The dose intensity administered per week was calculated
dividing the actual delivered dose by the length of the cycle (i.e.
3 weeks or longer in case of treatment delays). The relative dose
intensity was calculated by dividing the actual dose intensity by the
planned dose intensity.
RESULTS
Patient characteristics
In all, 40 patients were accrued between 18/03/96 and 04/06/98 into
this multicentre, nonrandomised, open-label phase II study. One
patient with an oesophageal adenocarcinoma was ineligible. Four
patients (10%) were not evaluable for response: one patient died
from cardiac congestive failure, another patient discontinued
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lbefore the first assessment due to febrile neutropenia and
diarrhoea and tumour assessments were not properly performed
in two other patients. In total, 35 patients (87.5%) were evaluable
for response. The patient characteristics for all patients are listed
in Table 1. The gender ratio (male/female) was 28/12 (70/30%).
The majority, 36 patients (90%), had a good performance status
(0–1). The median weight loss experienced was 5.0% (range: 0.0–
16.0). In all, 21 patients (52%) had undifferentiated tumours. A
total of 22 (55%) patients (21 evaluable patients) had had prior
surgery. In only 20% was it conducted with curative intent, 34
patients (85%) had one or two organs involved. A total of 30
patients (75%) had symptoms at baseline and of these, 28 (70%)
had at least one tumour-related symptom.
Drug delivery
In total, 40 patients received 163 cycles of irinotecan. The median
number of cycles per patient was 3 (range 1–14). The median dose
intensity was 114mgm
 2week
 1, with a median relative dose
intensity of 0.98. Of the 163 cycles 124 (76%) were administered at
the full dose; only 25% (10) of the patients, and 8.6% (14) of the
cycles were delayed, mostly for nondrug-related reasons. The dose
of irinotecan was reduced in 23% (9) of the patients, but in only
6.1% (10) of the cycles. The reasons for dose reduction were
haematological toxicity for two cycles, non–haematological
toxicity for five cycles and both for three cycles. Nine cycles were
delayed for 4–7 days and 5 cycles were delayed for more than 7
days. In total, 26 patients had neither a dose reduction nor a dose
delay. These data confirm the feasibility of both the dose and the
schedule.
Efficacy
Out of 35 evaluable patients, there were two confirmed complete
responses (CRs) and five confirmed partial responses (PRs). In
total, 16 patients had stable disease (SD) and 12 PD. The overall
response rate (Table 2), for the evaluable patient population, was
20.0% (95% CI: 8.4-36.9%), and 66% of the patients benefited from
tumour growth control. Of the 40 treated patients (intention-to-
treat (ITT) population), the overall response rate was 17.5% (95%
CI: 7.3–32.8%). The median time to first response was 2.9 months.
Two responses were observed at cycle 2, two responses (including
one CR) at cycle 4, one response (a CR) at cycle 8 and two
responses at cycle 9. For the complete responders, one patient
presented with multiple liver lesions at baseline, and the other with
a coeliac mass (39mm 28mm). Responses were observed at all
sites, although it should be mentioned that one patient categorised
as having SD experienced a CR for all sites except the skin, and one
patient categorised as PR experienced CR at the metastatic site
although the primary tumour remained. Among the seven
responding patients, the number of cycles of irinotecan adminis-
tered varied between six and 13 cycles. Of note, 16 patients had a
‘best response’ of no change (SD), during their treatment with
irinotecan. The median duration of response and disease
stabilisation was 4.4 months. In all, 17 (48.6%) patients had at
least one symptomatic improvement during treatment, which were
observed from the first (14 patients) and second (three patients)
cycles. Among them, five (14.3%) patients had a PR, 11 (31.4%)
patients had SD and one patient had PD. At the first tumour
assessment (at the end of cycle 2), a total of 12 (37.5%) patients out
of the 32 patients receiving a second cycle, reported a symptomatic
improvement.
The median TTP (Figure 1) was 3.0 months (95% CI: 2.3–4.4%).
The probability of being free from progression at 6 months was
26%. With a median follow-up of 9.6 months, the median survival
time (Figure 2) was 7.1 months (95% CI: 5.2–9.0%). The
probability of being alive at 6 and 9 months was 61.0 and 32.4%,
respectively. In all, 19 patients received further chemotherapy after
irinotecan discontinuation. For 10 of these patients, this consisted
Table 1 Treated patient characteristics
N¼40 %
Sex: male/female 28/12 70/30
Median age (range) 58.0 (36–74) —
Median weight loss during last 3 months
(range)
5% (0.0–16.0) —
Performance status (0–1–2) 13–23–4 33/58/10
Gastric adenocarcinoma 39 97.5
Undifferentiated 21 52.5
Well differentiated 17 42.5
Not available 2 5.0
Status
Metastatic with primary tumour 25 62.5
Metastatic without primary tumour 15 37.5
Number of organs involved
1–2 34 85.0
X3 6 15.0
Sites of disease
Lymph nodes 24 60.0
Liver 22 55.0
Lung 8 20.0
Others 14 35.0
Previous treatment
Prior radiotherapy (yes/no) 1/39 2.5/97.5
Prior surgery (yes/no) 22/18 55.0/45.0
Intent of surgery (curative/palliative) 8/14 20.0/35.0
Median time (months) between
surgery and study entry
4.0 (0.3–65.1)
Signs and symptoms
No symptom at baseline 10 25.0
Symptoms at baseline 30 75.0
At least one tumour-related
symptom
28 70.0
Table 2 Responses and response rate: patients evaluable for response
Response rate N¼35 %
Complete response 2 5.7
Partial response 5 14.3
No change 16 45.7
Progressive disease 12 34.3
Response rate (95%CI) 20.0 (8.4–36.9)
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Figure 1 Time to progression in patients evaluable for response.
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lof cisplatin and 5-FU. All but one of these 19 patients had
documented PD. The remaining patient went ‘off study’ after the
first cycle due to an adverse event, and received further treatment 3
weeks later.
Tolerance
In general, the safety profile of irinotecan was good and was found
to be consistent with the safety profile of the drug in other
indications (Table 3). Neutropenia grades 3–4 was the most
common haematological side effect and was experienced by 15
patients (38.5%) during 26 (16.5%) cycles. Four patients received
granulocyte-colony stimulating factor (G-CSF). No prophylactic G-
CSF was administered during the course of this study. Febrile
neutropenia occurred in five patients (12.5%) during six cycles
(3.7%). Infection with concomitant grade 3–4 neutropenia was
observed in one patient during one cycle. Diarrhoea was
commonly reported (77.5% (31) of the patients and in 44.2%
(72) of cycles). Overall, eight patients (20%) experienced severe
diarrhoea during 5.5% of cycles, and four of these required
hospitalisation. Nausea was frequent (62.5% (25) of patients, 37.4%
(61) of cycles), but was rarely severe (7.5% (3) of patients and 1.8%
(3) of cycles). Asthenia occurred in 20.0% (8) of the patients and
6.1% (10) of the cycles, but was also rarely severe 10.0% (4) of
patients and 2.5% (4) of cycles. Grade 1–2 alopoecia was common
(60% (24) of patients: 15% (6) grade 1 and 45% (18) grade 2).
Cholinergic syndrome was observed in 50% (20) of patients and in
21.5% (35) of cycles, but was never severe. One patient (69 years
old) died while on study: the patient experienced febrile
neutropenia, grade 1 diarrhoea and grade 1 dehydration and
hypocaliemia during cycle 2. Fluid substitution was followed by
deterioration of the patient’s general condition and the onset of a
lethal congestive cardiac failure. This death was considered to be
drug related by the investigator, as the patient had no relevant
previous history of cardiac disease.
DISCUSSION
This phase II study is the first reported European trial of irinotecan
for the treatment of metastatic gastric adenocarcinoma.
With an objective response rate of 20.0% including two CRs, this
study confirms that irinotecan is active in the treatment of this
dismal disease. The response rate deserves several comments.
Firstly, CRs are uncommon with single-agent treatment. The
occurrence of these CRs not only confirms the antitumour activity
of irinotecan, but ranks irinotecan among the most active agents in
this indication. Secondly, it is worth mentioning that due to the
activity of the drug, the responding patients were able to receive a
long period of treatment that was associated with a significant
clinical benefit. Thirdly, as already observed with irinotecan for
colorectal cancer, responses may occur at any time during
treatment, and justifies the continuation of the treatment in
patients experiencing clinical benefit from irinotecan.
A total of 46% of the evaluable patients had SD as their best
response, with a median duration of treatment of three cycles. This
corresponded to the number of patients (37.5%) who had
experienced a subjective improvement of their status at cycle 2.
With a median follow-up for survival of 9.6 months, the median
survival has been reached at 7.1 months, with a probability of
being alive at 9 months of 32.4%. However, this promising survival
may also be linked to the fact that 47.5% of the patients went on to
receive further active chemotherapy (principally of cisplatinum/5-
FU). Responses to the combination cisplatinum/5-FU have been
documented previously after irinotecan failure, but they were of
short duration (Thuss-Patience et al, 2002). Nevertheless, these
results show that other cytotoxics commonly used in the treatment
of gastric cancer are not cross-resistant with irinotecan. This had
already been suggested by Japanese data, where patients treated
with chemotherapy second line experienced some activity
(Futatsuki et al, 1994). However, currently there is no proof that
second-line chemotherapy treatment significantly improves survi-
val in patients with gastric cancer.
As mentioned earlier, several factors including the high median
dose intensity, the high percentage of cycles administered at the
full dose, the low proportion of delayed cycles (mostly for
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Figure 2 Survival in treated patients (ITT population).
Table 3 Grade 3–4 adverse events classified according to NCI-CTC
Patients (N¼40) N (%) Cycles (163) n (%)
Grade 3–4 NCI/CTC adverse events Grade 3 Grade 4 3+4 Grade 3 Grade 4 3+4
Anaemia
a 4 1 5 (12.8) 5 1 6 (3.7)
Leucopenia
a 5 6 11 (28.2) 11 7 18 (11.2)
Neutropenia
a 7 8 15 (38.5) 13 13 26 (16.5)
Thrombocytopenia
a — 2 2 (5.1) — 2 2 (1.2)
Febrile neutropenia 5 — 5 (12.5) 6 — 6 (3.7)
Infection with concomitant gr3–4 neutropenia 1 — 1 (2.5) 1 — 1 (0.6)
Diarrhoea 5 3 8 (20.0) 6 3 9 (5.5)
Asthenia 4 — 4 (10.0) 4 — 4 (2.5)
Nausea 3 — 3 (7.5) 3 — 3 (1.8)
Vomiting 2 — 2 (5.0) 2 — 2 (1.2)
Abdominal pain 1 1 2 (5.0) 1 1 2 (1.2)
aN¼39 evaluable patients (with at least one blood count). n¼161 evaluable cycles (with at least one blood count) except for neutropenia (n¼158 cycles).
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lnondrug-related reasons) as well as the low proportion of reduced
cycles (mostly for nonhaematological reasons), confirm the
feasibility of the dose and the schedule. Thus, irinotecan as a
single agent was very well tolerated in these patients. The
haematological and nonhaematological safety profiles observed
for the present cohort of patients with metastatic gastric cancer
compare favourably with the experience of irinotecan in patients
with advanced CRC. The incidence of severe diarrhoea (20.0%) is
comparable to that observed in phase II–III trials using high-dose
loperamide (Cunningham et al, 2000). The safety results of this
study were also similar to those obtained previously for irinotecan
in CRC patients. However, Egner et al (1999) reported the
excessive toxicity of irinotecan at a dose of 320mgm
 2, firstline,
in nine patients with advanced gastric or gastro-oesophageal
junction adenocarcinomas. Six of the nine patients in this study
were hospitalised for grade 4 toxicity (67%), prompting the
authors to conclude that the irinotecan dose of 350mgm
 2, while
tolerable in patients with CRC was too toxic in patients with gastric
cancer. The results of the current phase II study do not support
this conclusion, since the proportion of toxicity-related hospita-
lisations in this study was 25%, or 10 patients out of 40.
In conclusion, the activity of irinotecan in the treatment of
metastatic gastric cancer is confirmed. The present phase II trial
ranks irinotecan as one of the most active agents in this indication
based on the presence of confirmed CRs. Irinotecan is also well
tolerated, as demonstrated by the excellent relative dose intensity.
Based on these promising results, randomised phase II and III
trials of combination regimens including irinotecan are ongoing
(Pozzo et al, 2001) and will help to define the role of this drug
further in the treatment of gastric cancer.
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